9775838

5 known cases. View patent page →

Cases
5
Active
1
4 closed
Filed
2016–2019
Top venue
PTAB
3 cases

Filing activity

2016: 1 case'16'17'182019: 3 cases3'19
Cases asserting US Patent 9775838 filed per year.

Adapt Pharma Operations Limited et al. v. Teva Pharmaceuticals USA, Inc. et al.

judgment (invalidity); affirmed on appeal
Docket:
2:16-cv-07721 (JLL)(JAD); 2:17-cv-00864; 2:17-cv-02877; 2:17-cv-05100; 2:18-cv-09880
Filed:
2016-11-26
Terminated:
2020-06-26
Patents:9192570946874795611779629965977583810085937
π Adapt Pharma Operations Limitedπ Adapt Pharma Inc.π Adapt Pharma Limitedπ Opiant Pharmaceuticals, Inc.Δ Teva Pharmaceuticals USA, Inc.Δ Teva Pharmaceuticals Industries, Ltd.

Adapt and Opiant sued Teva in D.N.J. asserting NARCAN naloxone nasal spray patents. The district court found the asserted patents invalid for obviousness on June 5, 2020, with judgment entered June 26, 2020; the Federal Circuit affirmed on Feb. 10, 2022. The '570 patent was not asserted but was cited as prior art (Wyse). Consolidated/related docket numbers included 2:17-cv-00864, 2:17-cv-02877, 2:17-cv-05100, 2:18-cv-09880; related Perrigo action 2:18-cv-15287.

Adapt Pharma Operations Limited et al. v. Perrigo UK FINCO Limited Partnership

related action
Docket:
2:18-cv-15287
Patents:9192570946874795611779629965977583810085937
π Adapt Pharma Operations Limitedπ Adapt Pharma Inc.π Adapt Pharma Limitedπ Opiant Pharmaceuticals, Inc.Δ Perrigo UK FINCO Limited Partnership

Related Perrigo action in the D.N.J. NARCAN litigation; Perrigo UK FINCO Limited Partnership named as defendant. The '570 patent was not asserted; it was prior art (Wyse) in the related litigation.